A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

Also called NCT02914665

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 308 participants (enrolled count) (from the registry)
Sponsor
Stealth BioTherapeutics Inc. (from the registry)
Registry
  • NCT NCT02914665
  • EudraCT 2016-000126-19
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Bulgaria, France, Hungary, Latvia, Netherlands, Poland, Serbia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02914665. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-20 (actual); primary completion 2017-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
Condition
Heart Failure
Intervention (Drug)
elamipretide
Intervention (Drug)
Placebo
Lead sponsor
Stealth BioTherapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct02914665
Content hash
651293855fc78e4da969be0ed81edadd0ae6e6b371212faa9498cdfa1cfd0699